#United States #New York #Securities Fraud #Pomerantz LLP #Ultragenyx

Investigation into Ultragenyx Pharmaceutical Inc. by Pomerantz Law Firm

The Pomerantz Law Firm is actively probing allegations on behalf of investors involved with Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). This scrutiny comes amid growing concerns over potential securities fraud and other unlawful business practices within the pharmaceutical company.

Background on Ultragenyx

Ultragenyx specializes in the development of innovative therapies for rare diseases. However, the company faced a significant setback recently when it reported disappointing results from the Phase 3 Aspire study of apazunersen (GTX-102), targeted at treating Angelman syndrome. The findings, made public on September 2, 2026, indicated that the trial failed to meet both primary and key secondary endpoints.

This announcement led to a dramatic decline in Ultragenyx's stock price, plummeting $11.68 per share, a drop of 44.03%, closing at $14.85 on September 3, 2026. Such significant stock depreciation has sparked concerns among investors regarding the company’s transparency and business operations.

Potential Legal Implications

Pomerantz LLP is now investigating whether Ultragenyx, along with certain officers and directors, may have violated securities laws through misleading information or deceptive practices. For investors affected by the price drop who believe they have suffered losses, legal recourse may be available. The firm has called on stakeholders to reach out directly to discuss involvement in a potential class action lawsuit.

Pomerantz LLP: A Leader in Class Action Litigation

Pomerantz LLP, recognized as one of the leading firms in corporate and securities class litigation, boasts a rich history dating back over 85 years. The firm, founded by Abraham L. Pomerantz—often referred to as the pioneer of securities class actions—continues its mission to advocate for the rights of investors who fall victim to corporate misconduct.

Contacts at Pomerantz are urging any investors of Ultragenyx who are looking for legal assistance or more information on the ongoing investigation to get in touch. These steps could be vital for those aiming to assert their rights and potentially recover their investments.

Conclusion

The situation unfolding with Ultragenyx Pharmaceutical Inc. highlights critical issues regarding corporate governance and investor relations in the biotech sector. As investigations by Pomerantz LLP proceed, it raises awareness about the importance of transparency and accountability in pharmaceutical companies. Investors are encouraged to stay informed and consider their options carefully in light of this serious investigation. Investors can reach out to Danielle Peyton at Pomerantz for more information or to discuss their legal rights in connection to the situation at Ultragenyx.